| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/21/2002 | WO2002022124A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022122A1 Use of compounds for the treatment of obesity |
| 03/21/2002 | WO2002022120A1 Pain reliever and method of use |
| 03/21/2002 | WO2002022119A1 Use of rhein for preparing a medicine for preventing articular cartilage damage |
| 03/21/2002 | WO2002022118A1 Fungicidal agent containing n-chlorotaurine and use thereof |
| 03/21/2002 | WO2002022116A1 Volatile anaesthetic with xenon |
| 03/21/2002 | WO2002022115A2 Methods and compositions for treating nail fungus |
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022113A2 Retinoic acid receptor antagonists as promoters of angiogenesis |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002022110A2 Contraception process and administration form for the same |
| 03/21/2002 | WO2002022109A2 Patch comprising diclofenac |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2002022107A2 Pharmaceutical composition having modified carrier |
| 03/21/2002 | WO2002022106A2 Stable ophthalmic preparation |
| 03/21/2002 | WO2002022088A1 Hair nourishments and method of screening the same |
| 03/21/2002 | WO2002022087A1 Compositions containing a vitamin c component and pigment |
| 03/21/2002 | WO2002022074A2 Use of 2- and 4- quinolones for inhibiting intimal neo-proliferation |
| 03/21/2002 | WO2002021996A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | WO2002021934A1 Use of carnitine for enhancing training-induced bradycardia |
| 03/21/2002 | WO2002021933A2 Feedstuff or a feedstuff additive used as a performance promoter or as an appetite promoter for domestic animals |
| 03/21/2002 | WO2002011712A8 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 03/21/2002 | WO2002008186A3 Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| 03/21/2002 | WO2002006255A3 Hydroxy-(piperidin-4-yl-methylamino)-alkyl beta-3 adrenergic receptor antagonists |
| 03/21/2002 | WO2002006205B1 Method for preparing a fatty substance ester and use thereof in pharmaceutics, cosmetics or food industry |
| 03/21/2002 | WO2002004457A8 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 03/21/2002 | WO2002000024A8 New strategy for leukemia therapy |
| 03/21/2002 | WO2001096388A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 03/21/2002 | WO2001095920A8 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 03/21/2002 | WO2001095891A3 Method for treating dehydration and a composition therefor |
| 03/21/2002 | WO2001095858A3 Piperazinedione compounds |
| 03/21/2002 | WO2001093843A3 Benzoic acid esters having antiplasmid effect |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001085179A3 Biological joint lubricant composition and method of applying |
| 03/21/2002 | WO2001083457A3 Benzimidazole-2-carbamates and their use in cancer treatment |
| 03/21/2002 | WO2001081567A3 Method for producing genomic libraries and genomic libraries produced therewith |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001080829A3 Taste masking coating composition |
| 03/21/2002 | WO2001078703A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001077376A8 Diagnosis of diseases associated with metastasis |
| 03/21/2002 | WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 03/21/2002 | WO2001076631A3 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 03/21/2002 | WO2001076599B1 Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form |
| 03/21/2002 | WO2001076551B1 Cosmetic or pharmaceutical composition containing a sesquiterpene lactone |
| 03/21/2002 | WO2001074813A3 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
| 03/21/2002 | WO2001074365A3 An efficacious dosage regimen of galantamine that reduces side effects |
| 03/21/2002 | WO2001074345A3 Isoflavones for treatment of obesity |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001070672A3 Compounds and methods to treat alzheimer's disease |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001068092A3 Glycogen phosphorylase inhibitor |
| 03/21/2002 | WO2001068074A3 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 03/21/2002 | WO2001068034A3 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 03/21/2002 | WO2001066438A3 Pharmaceutical packaging system |
| 03/21/2002 | WO2001066103A3 Treatment of neoplasms by inhalation of carboplatin |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064252A3 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 03/21/2002 | WO2001064218A3 Farnesyl protein transferase inhibitor combinations |
| 03/21/2002 | WO2001064198A3 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 03/21/2002 | WO2001064197A3 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 03/21/2002 | WO2001064196A3 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 03/21/2002 | WO2001064195A3 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001060319A3 Polyhydroxylated benzene-containing compounds |
| 03/21/2002 | WO2001058954A3 Trade molecules and uses related thereto |
| 03/21/2002 | WO2001056548A3 Liposomes composition produced by a dehydration-rehydration process |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051057A3 Glycosides and orthoester glycosides of glucocorticoids and uses thereof |
| 03/21/2002 | WO2001051055A3 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 03/21/2002 | WO2001051026A3 Instant granules and process for their formulation |
| 03/21/2002 | WO2001049775A3 Antisense antibacterial cell division composition and method |
| 03/21/2002 | WO2001047935A3 Novel bisamidate phosphonate prodrugs |
| 03/21/2002 | WO2001047469A3 Treatment of ischemic brain injuries with brain targetted antioxidant compounds |
| 03/21/2002 | WO2001043732A3 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 03/21/2002 | WO2001043731A3 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 03/21/2002 | WO2001042205A3 Treatment of inflammatory bowel disease with vitamin d compounds |
| 03/21/2002 | WO2001041812A3 Amphiphilic polymers and polypeptide conjugates comprising same |
| 03/21/2002 | WO2001041754A3 Inhibitors of collagen-induced platelet aggregation |
| 03/21/2002 | WO2001041749A3 Combinations of sumatriptan or naratriptan with cyclooxygenase iiinhibitor |
| 03/21/2002 | WO2001040315A8 The alginate having low molecular weight, methods of manufacturing it and its use |
| 03/21/2002 | WO2001037876A3 Methods of ameliorating abnormal bone states |
| 03/21/2002 | WO2001037851A3 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies |
| 03/21/2002 | WO2001037832A3 Combination of riluzole and gabapentin and use thereof as medicine |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001035940A3 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 03/21/2002 | WO2001034136A3 Use of adatanserin for the treatment of neurodegenerative conditions |
| 03/21/2002 | WO2001034135A3 Oncolytic combinations for the treatment of cancer |
| 03/21/2002 | WO2001032160A3 Modification of cholesterol concentrations with citrus phytochemicals |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001030334A3 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |
| 03/21/2002 | WO2001014372A3 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/21/2002 | WO2001012176A3 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 03/21/2002 | WO2001010199A9 A knockout mouse for the tumor suppressor gene anx7 |